TrialLancet (London, England)2021

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

Alberto M Borobia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.